Companies › Multitude Therapeutics
4 active drug programs in 7 registered trials: 5 Phase 1, 2 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AMT-116 Antibody-drug conjugate | – | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer); Advanced Solid Tumors; Advanced Solid Tumor; Advanced Non-small Cell Lung Cancer (NSCLC) | Dec 2026 |
| AMT-676 | – | Phase 2 | Colorectal Cancer | Sep 2027 |
| AMT-253 | – | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| AMT-253 | – | Phase 1 | Malignant Melanoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06782334 | AMT-116 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT05725291 | AMT-116 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT05906862 | AMT-253 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06209580 | AMT-253 | Phase 1 | Malignant Melanoma | Oncology | Dec 2026 |
| NCT07590531 | AMT-116 | Phase 1 | Advanced Non-small Cell Lung Cancer (NSCLC) | Oncology | May 2027 |
| NCT07474727 | AMT-676 | Phase 2 | Colorectal Cancer | Oncology | Sep 2027 |
| NCT07718737 | AMT-116 | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | Mar 2028 |
No annotated target.
–
Avistone Biotechnology Jacobio Pharmaceuticals Tianjin ConjuStar Biologics DualityBio TORL Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.